Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT01656486 |
| Other study ID # |
07-12-16EM |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
July 2012 |
| Est. completion date |
November 2012 |
Study information
| Verified date |
February 2014 |
| Source |
Wake Forest University Health Sciences |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Patients that have undergone pre-operative radiation for pancreatic carcinoma, that upon
pathologic examination of the normal portion of the pancreatic gland that was in the
radiation field showed acute and chronic changes in the pancreatic cells. The hypothesis for
utilizing stereotactic radiation on pancreatic fistulae is that the treatment will decrease
pancreatic secretions, thus decreasing autodigestion.
Description:
Stereotactic radiation for cancer has been utilized to successfully treat the head of the
pancreas, which is generally a well-tolerated procedure with minimal complications. Upon
further investigation under the microscope, after resection during a complex Whipple
operation, it is noted that particularly the exocrine glandular tissue atrophied
substantially. Based on this information, the hypothesis for utilizing stereotactic radiation
on the remaining pancreas is production of a fibrosis of the pancreas and a decrease in the
production of exocrine portion of the gland. The use of stereotactic radiation will be
performed on individuals that are non-surgical candidates.
